Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy of weekly paclitaxel-carboplatin combination plus
bevacizumab as first line treatment in patients with metastatic triple negative breast
cancer. Furthermore, the efficacy of the combination therapy will be correlated with the
presence of circulating tumor cells (CTCs) in this population